Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Covid symbols : Nvs save search
Transdermal Drug Delivery - Global Market Trajectory Following COVID-19 Pandemic
Published: 2021-10-01 (Crawled : 17:00) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.16%
H: 0.0%
C: 0.0%
DRRX | $0.9019 -0.89% -0.9% 110K
|
Health Technology
|
| O: 0.0%
H: 4.69%
C: 2.34%
ATRS | $5.59 0.0%
|
Health Technology
|
| O: 0.55%
H: 0.55%
C: 0.0%
covid drug drug delivery liver covid-19
Smart Pills Global Market Report 2021: COVID-19 Growth and Changes to 2030
Published: 2021-08-06 (Crawled : 17:00) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.85%
H: 0.15%
C: -0.16%
MDT | $79.48 0.37% -0.29% 6.7M
|
Health Technology
|
| O: 0.55%
H: 0.0%
C: 0.0%
BSX | $67.33 -0.13% -0.31% 7M
|
Health Technology
|
| O: 0.13%
H: 0.06%
C: -0.02%
covid growth covid-19
Drug Delivery Devices Global Markets Report 2021: COVID-19 Impacts, Implications and Growth Factors to 2030
Published: 2021-08-06 (Crawled : 15:00) - prnewswire.com
WST | $372.04 -1.4% 0.0% 440K
|
Health Technology
|
| O: -0.71%
H: 1.44%
C: 1.15%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.85%
H: 0.15%
C: -0.16%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.16%
H: 0.0%
C: 0.0%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.95%
H: 0.23%
C: -0.3%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -0.05%
H: 0.0%
C: 0.0%
MMM | $92.27 0.86% -0.18% 3.6M
|
Producer Manufacturing
|
| O: 0.19%
H: 0.54%
C: -0.03%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.26%
H: 0.0%
C: 0.0%
OSUR | $5.27 0.38% 0.38% 660K
|
Health Technology
|
| O: 0.42%
H: 0.0%
C: -2.24%
PODD | $166.255 0.93% 0.92% 840K
|
Health Technology
|
| O: 0.91%
H: 0.0%
C: -2.64%
covid drug growth device drug delivery liver
$2.3 Billion Worldwide Spinal Cord Trauma Treatment Industry to 2027 - Impact of COVID-19 on the Market
Published: 2021-06-21 (Crawled : 19:00) - prnewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.03%
H: 0.71%
C: 0.51%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.65%
H: 0.25%
C: -0.18%
covid treatment spinal cord
Complications in COVID-19 leading to Heart Conditions Creates Unknown Opportunities in Cardiac Arrest Treatment Market: TMR
Published: 2021-06-17 (Crawled : 14:00) - prnewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.08%
H: 0.81%
C: 0.53%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.11%
H: 0.5%
C: 0.49%
PHG | $19.98 0.0% 540K
|
Health Technology
|
| O: -1.61%
H: 1.32%
C: 0.85%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.15%
H: 0.92%
C: 0.63%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.16%
H: 0.21%
C: -0.39%
BSX | $67.33 -0.13% -0.31% 7M
|
Health Technology
|
| O: -0.14%
H: 1.83%
C: 1.47%
covid treatment heart
Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19
Published: 2021-05-27 (Crawled : 06:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.4%
H: 0.26%
C: -0.36%
covid treatment molecular trial ensovibep
$ 3.43 Billion growth expected in Anaplastic Lymphoma Kinase (ALK) Inhibitors Market | 20.14% YOY growth in 2021 amid COVID-19 Spread | North America to Notice Maximum Growth | Technavio
Published: 2021-05-14 (Crawled : 23:00) - prnewswire.com
TECH | $62.12 -0.15% -0.14% 910K
|
Health Technology
| Email alert
Add to watchlist
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
| Email alert
Add to watchlist
covid growth
COVID-19 Impact Analysis on Sjogren's Syndrome Therapeutics Market | 3.68% YOY growth expected in 2021 | Technavio
Published: 2021-05-10 (Crawled : 11:00) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.05%
H: 0.37%
C: -0.02%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.83%
H: 0.96%
C: 0.22%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.54%
H: 0.7%
C: -0.14%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.54%
H: 0.17%
C: -0.32%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.3%
H: 1.41%
C: 0.27%
covid growth syndros covid-19
Vectura and Inspira Pharmaceuticals sign Agreement on Development of Potential Inhaled Treatment for COVID-19
Published: 2021-05-07 (Crawled : 18:00) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.55%
H: 0.39%
C: 0.15%
covid treatment potential covid-19
2021 COVID-19 News: Pfizer to File for Full Approval of Its Vaccine and More
Published: 2021-05-04 (Crawled : 15:00) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.82%
H: 0.28%
C: -0.06%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.23%
H: 1.83%
C: 1.78%
covid vaccine approval covid-19
Outlook on the End Stage Renal Disease Global Market to 2025 - Competitive Analysis and Impact of COVID-19
Published: 2021-04-13 (Crawled : 22:00) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.17%
H: 0.5%
C: 0.34%
MDT | $79.48 0.37% -0.29% 6.7M
|
Health Technology
|
| O: -0.02%
H: 1.02%
C: 0.24%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.67%
H: 0.11%
C: -0.41%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.27%
H: 0.33%
C: 0.09%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.56%
H: 0.18%
C: -0.4%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.01%
H: 0.61%
C: -0.14%
covid disease renal
$1.1 Billion Worldwide Spinal Muscular Atrophy Industry to 2027 - Impact of COVID-19 on the Market
Published: 2021-04-09 (Crawled : 17:00) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.2%
H: 0.6%
C: 0.45%
IONS | $40.64 -0.42% -0.42% 850K
|
Health Technology
|
| O: -0.45%
H: 1.13%
C: -0.33%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.0%
H: 1.08%
C: 0.92%
covid covid-19 muscular atrophy
$833+ Million Krabbe Disease Treatment Industry to 2027 - Impact of COVID-19 on the Market
Published: 2021-04-08 (Crawled : 20:00) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.2%
H: 0.6%
C: 0.45%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.52%
H: 0.5%
C: -0.54%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -0.11%
H: 1.07%
C: 1.04%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.18%
H: 0.79%
C: 0.57%
covid disease treatment covid-19
Molecular Partners Announces First Patient Dosed in a Phase 2 Clinical Trial of Ensovibep in COVID-19 Patients
Published: 2021-04-06 (Crawled : 13:35) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.41%
H: 0.67%
C: -0.63%
covid phase 2 molecular trial ensovibep
Incyte Announces Results from the Phase 3 DEVENT Study Evaluating Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) on Mechanical Ventilation
Published: 2021-03-18 (Crawled : 22:00) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.56%
H: 0.83%
C: 0.02%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -1.05%
H: 0.86%
C: -1.4%
covid treatment results respiratory phase 3 syndros
Global Systemic Aspergillosis and Systemic Candidiasis Market Forecast to 2027 - COVID-19 Impact and Analysis
Published: 2021-03-18 (Crawled : 17:00) - prnewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.73%
H: 1.24%
C: 0.68%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.56%
H: 0.83%
C: 0.02%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.17%
H: 0.91%
C: 0.19%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.45%
H: 0.7%
C: 0.43%
covid system covid-19
Molecular Partners and Novartis Announce Inclusion of COVID-19 Antiviral Candidate, ensovibep, in NIH-Sponsored ACTIV-3 Trial
Published: 2021-03-15 (Crawled : 10:00) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.25%
H: 1.17%
C: 1.13%
covid antiviral molecular trial ensovibep
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
WLGS | $0.59 18.0% 17.9% 2.3M
|
UONE | $2.36 19.8% 16.53% 75K
|
Consumer Services
RWOD | $9.54 19.3% 16.18% 6.1M
|
n/a
BSFC | $0.0758 17.7% 15.04% 92M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.